Search: id:"swepub:oai:DiVA.org:umu-126800" >
Low-dose rate brach...
-
Rasmusson, ElisabethLund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital
(author)
Low-dose rate brachytherapy with I-125 seeds has an excellent 5-year outcome with few side effects in patients with low-risk prostate cancer
- Article/chapterEnglish2016
Publisher, publication year, extent ...
-
Oxon :Taylor & Francis,2016
-
printrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:umu-126800
-
https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-126800URI
-
https://doi.org/10.1080/0284186X.2016.1175659DOI
-
https://lup.lub.lu.se/record/e6328178-de1d-42ca-bf06-1dca262b3a3fURI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Background: Low-dose rate brachytherapy (LDR-BT) has been used in Sweden for more than a decade for treatment of low-risk prostate cancer. This study presents the outcome for patients treated with LDR-BT at a single institution with focus on the association between dose and biochemical failure-free survival (BFFS).Methods: In total 195 patients were treated with LDR-BT between 2004 and 2008. The patients were followed systematically for side effects for at least one year. PSA levels were followed regularly from three months and for at least five years. Outcome was analyzed in relation to clinical variables at baseline and to radiotherapy data.Results: Kaplan-Meier estimated BFFS at five years was 95.7%. Dose to the prostate in terms of D-90% was significantly associated with BFFS [HR 0.90 (95%CI 0.83-0.96), p=0.002].Conclusion: Out data confirmed that absorbed dose is a predictive factor for BFFS for low-risk patients without androgen deprivation therapy. With our treatment routines and dosimetry, a D-90% in the range of 170-180Gy gives excellent outcomes with acceptable toxicity for patients with low-risk prostate cancer.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Gunnlaugsson, AdalsteinnLund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital(Swepub:lu)onk-agg
(author)
-
Kjellén, ElisabethLund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital(Swepub:lu)onk-ekj
(author)
-
Nilsson, PerLund University,Lunds universitet,Medicinsk strålningsfysik, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Radiotherapy Physics,Forskargrupper vid Lunds universitet,Medical Radiation Physics, Lund,Section V,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund University Research Groups,Skåne University Hospital(Swepub:lu)rafy-per
(author)
-
Einarsdottir, MargretSkåne University Hospital
(author)
-
Wieslander, ElinoreLund University,Lunds universitet,Medicinsk strålningsfysik, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Medical Radiation Physics, Lund,Section V,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital(Swepub:lu)radf-ewi
(author)
-
Fransson, PerUmeå University,Lund University,Lunds universitet,Umeå universitet,Institutionen för omvårdnad,Öron-, näs- och halssjukdomar, Lund,Sektion IV,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Otorhinolaryngology (Lund),Section IV,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)onh-paf
(author)
-
Ahlgen, GöranSkåne University Hospital
(author)
-
Blom, RenéLund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital(Swepub:lu)med-reb
(author)
-
TumörmikromiljöSektion I
(creator_code:org_t)
Related titles
-
In:Acta OncologicaOxon : Taylor & Francis55:8, s. 1016-10210284-186X1651-226X
Internet link
Find in a library
To the university's database